FDA Panel Recommends Approval For InterMune's Esbriet

March 10, 2010 10:45 AM |
A Food and Drug Administration advisory panel recommended approval for InterMune Inc.'s (Nasdaq: ITMN) fatal lung disease treatment Esbriet sending the stock price soaring $14.88 to $38.18.

 

 

Tags:

Search

About this Entry

This page contains a single entry by published on March 10, 2010 10:45 AM.

Fund Manager Says Citigroup Underpriced was the previous entry in this blog.

FDA Panel Recommends Approval For InterMune's Esbriet is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12